Regenerative Medicine - Round 34 - (December 2012)

One $30,000, eight $50,000, and two $100,000 one-year awards funded:
  • Emory/Georgia Tech Regenerative Medicine and Engineering Center (from 28 submitted applications)
    • John Oshinski, PhD (Medicine, Radiology & Imaging Sciences, Emory University), Magnetic Resonance-Guided, Minimally Invasive, Percutaneous, Targeted Delivery of Cellular and Molecular Therapeutics to the Human Spinal Cord
    • Edward Mocarski, MD, PhD (Medicine, Microbiology & Immunology, Emory University), Balancing cell activation and death signals in reprogramming and regeneration
    • Edmund Waller, MD, PhD (Medicine, Hematology & Medical Oncology, Emory University), Ex-vivo expanded autologous mesenchymal stromal cells to treat graft versus host disease
    • Chunhui Xu, PhD (Medicine, Pediatrics, Emory University), Generation of Engineered Cardiac Constructs from Human Pluripotent Stem Cells
    • Ahsan Husain, PhD (Medicine, Cardiology, Emory University), Improving cardiac function through cardiomyogenesis
    • Luke Brewster, MD, PhD (Medicine, Surgery, Emory University), Preconditioning Human MSCs from Amputated Ischemic Limbs for Autologous Clinical Application
    • Mark Allen, PhD (Electrical & Computer Engineering, Georgia Tech), Microfabricated Bioinert and Biodegradable Wireless Sensors for In Situ Quantification of Mechanical Strains in Tissue Engineered Scaffolds
    • Brandon Dixon, PhD (Biomedical Engineering, Joint Georgia Tech/Emory), Dermal delivery of endothelin-1 and nitric oxide inhibitors to regenerate lymphatic pumping in a novel lymphedema model
    • Todd McDevitt, PhD (Biomedical Engineering, Joint Georgia Tech/Emory), Delivering Pluripotent Stem Cell Trophic Factors for Bone Marrow Regeneration
    • Julie Champion, PhD (Chemical & Biomolecular Engineering, Georgia Tech), Protein Biomaterials to Control Inflammation and Tolerance in Regenerative Medicine
    • Michelle Dawson, PhD (Chemical & Biomolecular Engineering, Georgia Tech), Anti-Angiogenic Mesenchymal Stem Cell-Based Therapy for Metastatic Melanoma